Incidence rates of malaria, meningitis, and mortality in children younger than 5 years: a prospective cohort study in Ghana and Kenya before the roll-out of the RTS,S/AS01E malaria vaccine from 2016 to 2022
Rattachement africain : Ghana, be, Kenya. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: implementation. Interim results from EPI-MAL-002 up to Oct 5, 2018, were reported previously. Here, we report results from the final analysis of the pre-vaccine introduction study. METHODS: vaccination schedule [ie, a simulated vaccination schedule], with additional visits after the simulated schedule and continuous disease monitoring of outpatient visits and hospital admission) in children enrolled in two age groups (6-12 weeks [6-12W] and 5-17 months [5-17M]), and (2) hospital-based disease surveillance for children not enrolled in the prospective cohort, in three sites in Ghana and Kenya. Key outcomes were rates of meningitis, malaria, adverse events of special interest, other adverse events leading to hospital admission, all-cause mortality, and malaria-attributable mortality. FINDINGS: vaccination), the incidence rates of meningitis and cerebral malaria within an at-risk period of 1 year after the simulated vaccination schedule were both equal to 28 (95% CI 9-65) per 100 000 person-years. There were 11 (0·1%) children with an adverse event of special interest during hospital admission. In the 5-17M age group, the all-cause mortality rate was 643 (95% CI 531-771) per 100 000 person-years. INTERPRETATION: . FUNDING: GSK and PATH.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Incidence rates of malaria, meningitis, and mortality in children younger than 5 years: a prospective cohort study in Ghana and Kenya before the roll-out of the RTS,S/AS01E malaria vaccine from 2016 to 2022
- Date Crossref
- 01/05/2025
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Kintampo Health Research Centre Ghana (code pays fourni par la source)Établissement de santé
-
Ghana Health Service Ghana (code pays fourni par la source)Organisme public
-
GlaxoSmithKline (Belgium) pays non établi dans la noticeEntreprise
-
United States Army Medical Research Directorate - Africa Kenya (code pays fourni par la source)Organisme public
-
Navrongo Health Research Centre Navrongo Health Research Centre, Ghana (code pays fourni par la source)Établissement de santé
-
Wavre pays non établi dans la noticeInstitution
-
GSK pays non établi dans la noticeInstitution
-
Kenya Medical Research Institute (KEMRI)-Walter Reed Project Kenya (pays nommé en fin d’affiliation)Structure de recherche
Kintampo Health Research Centre (Ghana), Ghana Health Service (Ghana) et GlaxoSmithKline (Belgium), avec 5 autres affiliations. Pays d’affiliation : Ghana, Kenya.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.